Last updated: February 23, 2026
What is SOMA (Carisoprodol)?
SOMA, with the generic name carisoprodol, is a prescription skeletal muscle relaxant approved by the U.S. Food and Drug Administration (FDA) in 1959. It is used for short-term relief of acute musculoskeletal pain. It is scheduled as a controlled substance due to its potential for abuse and dependence.
What are the key market drivers and constraints?
Drivers
- Demand for short-term muscle relaxants: SOMA remains prescribed for acute musculoskeletal conditions, especially where non-pharmacological interventions are insufficient.
- Healthcare provider familiarity: Long-standing approval and prescribing habits reinforce ongoing demand.
- Limited competition for same category drugs: Few drugs directly compete with SOMA for short-term relief, sustaining its relevance.
Constraints
- Regulatory restrictions: The DEA classifies SOMA as a Schedule IV substance since 2017, limiting prescribing to 3-week durations and reducing misuse.
- Risks of dependence: Growing awareness of abuse potential prompts tighter prescribing guidelines.
- Market saturation: Alternatives such as cyclobenzaprine or methocarbamol offer similar efficacy with potentially lower abuse risks.
- Legal liabilities and liability shifts: Some states are restricting or banning SOMA use.
Market size and demand trends
Prescription volume
- US prescriptions for SOMA have declined over the past decade, from approximately 4 million prescriptions in 2013 to below 2 million in 2021 (IQVIA, 2022).
- Post-2017 Schedule IV classification led to a 22% reduction in prescription volume within three years.
Revenue estimates
| Year |
Estimated US Sales (USD millions) |
Change from Previous Year |
| 2015 |
$60 |
— |
| 2019 |
$48 |
-20% |
| 2021 |
$42 |
-12.5% |
Market decline is primarily tied to regulatory restrictions and a shift toward alternative therapies.
Global Outlook
- The US represents approximately 85% of global SOMA sales; markets in Europe and Asia are minimal due to regulatory hurdles and availability.
- No significant off-label or OTC markets exist.
Financial trajectory: Key insights
Revenue projections (2023–2027)
- Expected decline: Compound annual growth rate (CAGR) of approx. -4% due to shrinking prescription numbers.
- Market stabilization: Possible plateau around USD 40-45 million annually if restrictions tighten or if prescribing stabilizes.
Cost considerations
- Manufacturing costs: Moderately stable; small economies of scale available.
- R&D investment: Minimal—SOMA is an off-patent drug with no new formulations announced.
- Regulatory costs: Likely to increase due to compliance, arbitrations on Schedule IV status, and potential litigation.
Competitive landscape
| Company |
Product Portfolio |
Market Position |
Regulatory status |
| Pfizer |
No current SOMA product |
Turned away from muscle relaxants |
N/A |
| Teva |
No discrete SOMA product |
No new SOMA offerings |
N/A |
| Mylan/Merck |
Limited muscle relaxants |
Focus on generics |
N/A |
SOMA’s market share diminishes as newer, less regulated drugs replace it. No recent patent filings or new formulations suggest limited long-term growth prospects.
Policy landscape impact
- The DEA's Schedule IV classification reduces abuse but constrains prescribing.
- State-level restrictions, including bans in some jurisdictions, decrease overall access.
- Potential reclassification or scheduling adjustments could either limit or expand utilization.
Key takeaways
- SOMA’s market is in decline, mostly due to regulatory restrictions, safety concerns, and competition.
- US prescription volume dropped by over 50% since 2013; revenue follows this trend.
- The global market remains negligible outside the US.
- Future financial performance is likely to plateau or decline unless regulatory reforms or innovative formulations emerge.
- The drug’s status as an off-patent compound limits investment in new developments.
FAQs
1. Is SOMA still available in the US?
Yes. It is available via prescription but subject to Schedule IV restrictions, with declining prescription rates.
2. Are there any generic versions of SOMA?
Yes. Several generic manufacturers produce carisoprodol, contributing to price competition and reduced revenue.
3. Could regulatory changes increase its market?
Possible, if reclassification reduces restrictions. Conversely, tighter controls or bans could further decrease demand.
4. Are other drugs replacing SOMA?
Yes. Cyclobenzaprine, methocarbamol, and tizanidine are preferred options with fewer abuse concerns and similar efficacy.
5. What is the outlook for investment in SOMA-related R&D?
Minimal. As an off-patent drug facing regulatory and market decline, significant R&D investment is unlikely unless new formulations or indications are developed.
References
- IQVIA. (2022). National Prescription Audit.
- U.S. Food and Drug Administration. (2017). Schedule IV designation for carisoprodol.
- Substance Abuse and Mental Health Services Administration. (2019). Prescription drug abuse statistics.
[1] U.S. Food and Drug Administration. (2017). "SOMA (Carisoprodol) FDA Drug Safety Communication."
[2] IQVIA. (2022). "US Prescription Trends."
[3] Substance Abuse and Mental Health Services Administration. (2019). "2019 Prescription Drug Abuse Statistics."
